Ohio State University Comprehensive Cancer Center
🇺🇸United States
Interim Digital PET/CT in Predicting Outcomes for Participants With Locally Advanced Oropharyngeal Cancer Undergoing Chemoradiation Therapy
Not Applicable
Withdrawn
- Conditions
- Oropharyngeal Squamous Cell CarcinomaHPV Positive Oropharyngeal Squamous Cell Carcinoma
- Interventions
- Procedure: Computed TomographyProcedure: Positron Emission Tomography
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
Phase 1
Completed
- Conditions
- Recurrent Grade 1 Follicular LymphomaRecurrent Grade 2 Follicular LymphomaRefractory Follicular LymphomaRefractory Marginal Zone LymphomaRefractory Non-Hodgkin LymphomaRefractory Transformed Indolent Non-Hodgkin LymphomaHematopoietic Cell Transplantation RecipientRecurrent Diffuse Large B-Cell LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Marginal Zone Lymphoma
- Interventions
- Procedure: Hematopoietic Cell Transplantation
- First Posted Date
- 2018-07-11
- Last Posted Date
- 2025-05-14
- Target Recruit Count
- 19
- Registration Number
- NCT03583424
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Stress and Immunity Breast Cancer Project
Not Applicable
Completed
- Conditions
- Breast Cancer Stage IIIBreast Cancer Stage II
- Interventions
- Behavioral: BioBehavioral Intervention
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2018-07-06
- Target Recruit Count
- 231
- Registration Number
- NCT03578627
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
Sensorimotor Rehabilitation Program in Improving Quality of Life in Patients With Early Stage Breast Cancer
Not Applicable
Completed
- Conditions
- Stage IB Breast Cancer AJCC v7Stage I Breast Cancer AJCC v7Stage II Breast Cancer AJCC v6 and v7Peripheral NeuropathyStage IA Breast Cancer AJCC v7Stage IIB Breast Cancer AJCC v6 and v7Stage IIA Breast Cancer AJCC v6 and v7
- Interventions
- Other: Educational InterventionBehavioral: Exercise InterventionOther: Quality-of-Life AssessmentOther: Questionnaire AdministrationOther: Survey Administration
- First Posted Date
- 2018-06-26
- Last Posted Date
- 2022-10-12
- Target Recruit Count
- 36
- Registration Number
- NCT03568526
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants with Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer
Phase 1
Completed
- Conditions
- Folate Receptor Alpha PositiveRecurrent Uterine Serous CarcinomaBRCA2 Gene MutationRecurrent Ovarian CarcinomaBRCA1 Gene MutationRecurrent Uterine CarcinosarcomaPlatinum Resistant Ovarian CancerRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal CarcinomaRecurrent Uterine Corpus Carcinoma
- Interventions
- Other: Laboratory Biomarker AnalysisOther: Pharmacokinetic Study
- First Posted Date
- 2018-06-11
- Last Posted Date
- 2025-02-13
- Target Recruit Count
- 25
- Registration Number
- NCT03552471
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ketogenic Diet and Chemotherapy in Affecting Recurrence in Patients With Stage IV Breast Cancer
Not Applicable
Completed
- Conditions
- Stage IV Breast Cancer AJCC v6 and v7
- Interventions
- Other: Laboratory Biomarker AnalysisDietary Supplement: Dietary InterventionOther: Quality-of-Life AssessmentOther: Questionnaire Administration
- First Posted Date
- 2018-05-24
- Last Posted Date
- 2021-09-08
- Target Recruit Count
- 20
- Registration Number
- NCT03535701
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Indocyanine Green Lymphangiography in Identifying Thoracic Duct During Neck Surgery
Not Applicable
Completed
- Conditions
- Neck DissectionRadical Lymph Node Dissection
- Interventions
- Other: Indocyanine Green SolutionProcedure: Lymphangiography
- First Posted Date
- 2018-05-22
- Last Posted Date
- 2024-01-16
- Target Recruit Count
- 48
- Registration Number
- NCT03532581
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Ibrutinib and Nivolumab in Treating Participants With Metastatic Solid Tumors
Phase 1
Completed
- Conditions
- Metastatic Malignant Solid Neoplasm
- Interventions
- First Posted Date
- 2018-05-16
- Last Posted Date
- 2024-03-18
- Target Recruit Count
- 16
- Registration Number
- NCT03525925
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Venetoclax and Ibrutinib in Treating in Participants with Chronic Lymphocytic Leukemia and Ibrutinib Resistance Mutations
Phase 2
Active, not recruiting
- Conditions
- Chronic Lymphocytic LeukemiaIbrutinib Resistance
- Interventions
- First Posted Date
- 2018-05-01
- Last Posted Date
- 2025-03-25
- Target Recruit Count
- 28
- Registration Number
- NCT03513562
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Switching to a Vaping Device: Evaluating Risk Reduction Among Quitline Treatment Failures
Not Applicable
Completed
- Conditions
- Smoking, Cigarette
- Interventions
- Other: Treatment As UsualDevice: JUUL
- First Posted Date
- 2018-04-18
- Last Posted Date
- 2023-07-21
- Target Recruit Count
- 350
- Registration Number
- NCT03502200
- Locations
- 🇺🇸
Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath